BMC-2012

N/A

Report date: 2023/01/07 18:43:59

Base Information

Drug NameBMC-2012

Drug Alias NameBone Marrow-derived Mononuclear CellsBMC-2012

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsFractures, Bone

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesGoethe University Frankfurt

China Registration ClassN/A

Develop Information

Active CompaniesGoethe University Frankfurt

Inactive CompaniesN/A

Active IndicationsFractures, Bone

Inactive IndicationsN/A

Other Information

ATC CodeN/A